CADTH Canadian Drug Expert Committee recommendation: Ranolazine (Corzyna -- KYE pharmaceuticals Inc.) indication: patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium...

Full description

Bibliographic Details

Corporate Author:	CADTH Canadian Drug Expert Committee
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health May 2021, 2021
Edition:	Version: Final
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK583807
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa